About 100 reports

  • GLOBAL REGENERATIVE MEDICINE MARKET BY OTHER APPLICATIONS

Approximately ##% of clinical trials of regenerative medicine are being conducted in oncology indications such as leukemia, lymphoma, brain cancer, breast cancer, bladder cancer, cervix cancer, colon cancer, esophageal cancer, ovarian

  • Regenerative Medicine
  • Medtronic, Inc.
  • MiMedx Group, Inc.
  • Organogenesis, Inc.
  • Zimmer Biomet Holdings, Inc.
  • GENE TRANSFER

Larger studies are being conducted for the treatment of rectal, esophageal, pancreatic cancer, and melanoma.

  • Regenerative Medicine
  • Therapy
  • Forecast
  • Market Size
  • Celgene Corporation
  • CAR-T Cell Therapies in Phase II or Above for Solid Tumors

Clinical Targets Being Investigated for CAR Cell Therapies in Solid Tumors by Organ Group KEY TARGETS ARE EMERGING FOR CERTAIN CANCER TYPES, WITH IMPORTANT TARGETS IN OTHER CANCERS NOT SO WELL DEFINED EPCAM CD## Mesothelin Multiple PSMA FOLR## MET MUC## DLLR## PMEL Source: GlobalDat

  • Regenerative Medicine
  • United States
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

CRISPR Edited cells might cause cancer.

  • Regenerative Medicine
  • Casebia Therapeutics LLP
  • Editas Medicine, Inc.
  • Novartis AG
  • Pfizer Inc.

Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer.

  • Regenerative Medicine
  • Therapy
  • United States
  • Celsion Corporation
  • Takara Bio Inc.
  • TBI-1501 / CD19 CAR-T
  • 14. MARKET SIZING AND OPPORTUNITY ANALYSIS

Therapy PHASE I / II ## LCAR-B##M CAR-T PHASE I / II T-CELL THERAPY (CAR-T) PHASE I / II LENTIVIRAL Indication R/ R CD-##+ CHRONIC LYMPHOCYTIC LEUKEMIA R/ R CD-##+ CHRONIC LYMPHOCYTIC LEUKEMIA RELAPSE AND REFRACTORY MULTIPLE MYELOMA SYNOVIAL SARCOMA (NY-ESO- ##+) SYNOV

  • Regenerative Medicine
  • Market Size
  • Supply
  • Lonza Group Ltd
  • Sanofi S.A.
  • 8.2 TABLE OF ALL PIPELINE PRODUCTS

Cancer; ##(##): ##.

  • Regenerative Medicine
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG

A PHASE II/ III TRIAL COMBINING ONCORINE WITH CHEMOTHERAPY WAS CONDUCTED IN ## PATIENTS WITH HNSCC OR ESOPHAGEAL CANCER.

  • Regenerative Medicine
  • North America
  • United States
  • Company
  • Market Size

IN ADDITION, LUMMY HK ACQUIRED THE RIGHTS TO DEVELOP PRODUCTS BASED ON THE ARCELIS PLATFORM FOR ADDITIONAL ONCOLOGICAL INDICATIONS, INCLUDING GASTRIC CANCER, ESOPHAGEAL CANCER, RECTAL CANCER, LUNG CANCER, LIVER CANCER, STOMACH CANCER AND PANCREAT

  • Regenerative Medicine
  • North America
  • United States
  • Argos Therapeutics, Inc.
  • Lonza Group Ltd

The drug candidate is in Phase II stage for the treatment of squamous and non-squamous non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, gastric cancer and advanced hepatocellular carcinoma (HCC).

  • Cancer
  • Regenerative Medicine
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

It was also under development for the treatment of colorectal, metastatic prostate cancer, bone metastasis, transitional cell cancer, germ cell tumors, ovarian cancer and esophageal cancer.

  • Cancer
  • Lung Cancer
  • Regenerative Medicine
  • Therapy
  • Geron Corporation

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR THE TREATMENT OF SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, ESOPHAGEAL CANCER, CHOLANGIOCARCINOMA, AND GASTRIC CANCER.

  • Cancer
  • Regenerative Medicine
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

Several studies have suggested that IGFs play a role in diseases such as cancer and diabetes, indicating that IGF-## stimulates the growth of breast cancer and prostate cancer cells, although there is not agreement among researchers regarding the degree of

  • Regenerative Medicine
  • United States
  • ConvaTec Inc.
  • Covidien plc
  • Smith & Nephew Plc

Currently, one in five patients with potentially curable lung cancer are not fit enough to undergo the standard treatment of operation or radiotherapy, but we can now treat these patients using navigational bronchoscopy.

  • Clinical Trial
  • Hepatitis
  • Regenerative Medicine
  • United States
  • AngioDynamics, Inc.

## ## ## ## ## ## ## ## ## ## ## ## GlaxoSmithKline Plc Galera Therapeutics Inc Novartis AG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## MallInckrodt Plc Jazz Pharmaceuticals Plc Eisai Co Ltd CD Pharma India Pvt Ltd Biotec Pharmacon ASA Sourc

  • Cancer
  • Clinical Trial
  • Regenerative Medicine
  • World
  • Product Initiative

The Checkmate ## trial will randomize approximately ## adults with resected esophageal cancer or gastro esophageal junction cancer who have received chemo radiotherapy followed by surgery.

  • Antibiotic Resistance
  • Blood Disease
  • Regenerative Medicine
  • Therapy
  • Bristol-Myers Squibb Company
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

Hoffmann-La Roche Ltd ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## Eisai Co Ltd ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Source: GlobalData' s Pharma Intelligence Center Cl

  • Immunotherapy
  • Pharmaceutical
  • Regenerative Medicine
  • Therapy
  • Merck & Co., Inc.

The prominent features of this report are - ##.

  • Pharmaceutical
  • Regenerative Medicine
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 373 Trial Title
  • Clinical Trial profile. 309 Trial Title

Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver GDCT## NCT##, MTC-DOX-##; NCT## Oncology Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastroin

  • Clinical Trial
  • Hepatitis
  • Regenerative Medicine
  • Therapy
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Pharmaceutical
  • Regenerative Medicine
  • World
  • Product Initiative

Tumor shrinkage was observed in ## (##. ##%) patients in multiple tumor types with ## unconfirmed partial responses (## each in ovarian and breast cancers and one in head and neck cancer).

  • Drug Development
  • Regenerative Medicine
  • United States
  • World
  • Product Initiative
  • 5.3 MARKET DYNAMICS

The survival rate for some of the cancers after five years of diagnosis and treatment is very low-for pancreatic cancer, ##%; liver cancer, ##%; lung cancer, ##%; esophageal cancer, ##%; and stomach cancer, ##% (American Cancer Society).

  • Pharmaceutical
  • Regenerative Medicine
  • North America
  • United States
  • Market Size

CLINICAL TRIALS BY PHASE IN G## COUNTRIES SALIVARY GLAND CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SALIVARY GLAND CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SALIVARY GLAND CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY

  • Regenerative Medicine
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative

It conducts research on various diseases such as cervical cancer, colorectal cancer, crohn' s disease, cystic fibrosis, esophageal cancer, influenza, kaposi sarcoma, barrett' s esophagus, brain tumors, breast cancer, leukemia, lung

  • Cell Therapy
  • Regenerative Medicine
  • Therapy
  • United States
  • Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Immunotherapy
  • Regenerative Medicine
  • Therapy
  • World
  • Product Initiative

TRANSITIONAL CELL CANCER (UROTHELIAL CELL CANCER) THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* CLINICAL TRIALS BY PHASE IN E## COUNTRIES TRANSITIONAL CELL CANCER (UROTHELIAL CELL CANCER) THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* TRA

  • Clinical Trial
  • Monoclonal Antibody
  • Regenerative Medicine
  • United States
  • World
  • CAN-04 - DRUG PROFILE

The Checkmate ## trial will randomize approximately ## adults with resected esophageal cancer or gastro esophageal junction cancer who have received chemoradiotherapy followed by surgery.

  • Cell Therapy
  • Leukemia
  • Regenerative Medicine
  • Therapy
  • Bristol-Myers Squibb Company

SQUAMOUS NON-SMALL CELL LUNG CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* CLINICAL TRIALS BY PHASE IN E## COUNTRIES SQUAMOUS NON-SMALL CELL LUNG CANCER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SQUAMOUS NON-SMALL CELL LUNG CANCER THER

  • Lung Cancer
  • Pharmaceutical
  • Regenerative Medicine
  • World
  • Product Initiative

Among these, small-cell lung cancer, recurrent after one chemotherapy prior line.

  • Drug Development
  • Lung Cancer
  • Pharmaceutical
  • Regenerative Medicine
  • World

PharmaMar will also host a satellite symposium on " The key role of quality of life in the long-distance race of ovarian cancer" on Saturday, the ##th of November at ## p. m.

  • Drug Development
  • Medical Biotechnology
  • Regenerative Medicine
  • World
  • Product Initiative